Product Description
MRX2843 is a novel, potent, and bioavailable small-molecule oral inhibitor, which is a dual inhibitor of MERTK and FLT3. MERTK and FLT3 are overexpressed or mutated in a variety of tumors. MRX2843 can affect tumor growth by inhibiting MERTK and FLT3 in tumor cells and innate immune cells in tumor microenvironment, thereby affecting the key signal transduction pathways or immunomodulation to inhibit tumors. The clinical trial of MRX2843 for advanced solid tumor has been approved, and it is ongoing. (Sourced from: http://www.bettapharma.com/en.php/Newdrug/projects)
Mechanisms of Action: FLT3 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Meryx, Inc.
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Acute Lymphoid Leukemia|Acute Myeloid Leukemia|Oncology Solid Tumor Unspecified|Precursor Cell Lymphoblastic Leukemia-Lymphoma
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT04872478 |
NCT04872478 | P1 |
Recruiting |
Precursor Cell Lymphoblastic Leukemia-Lymphoma|Acute Myeloid Leukemia|Acute Lymphoid Leukemia |
2025-12-31 |
43% |
2024-11-21 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
NCT03510104 |
NCT03510104 | P1 |
Active, not recruiting |
Oncology Solid Tumor Unspecified |
2025-02-01 |
21% |
2024-11-21 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |